Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
NCT05032599
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
OTHER
Sponsor class
Stopped
ethic commitee decision
Conditions
T-Cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL:
CD5 CART
Sponsor
Beijing Boren Hospital